Jaypirca's Impact on CLL Treatment
- Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma treatment has undergone a dramatic transformation in recent years.
- Oncologists once relied on intensive combination chemotherapy; conversely, today’s standard of care is built around targeted, largely oral therapies that are easier for patients to tolerate and, in many cases, simple enough to take at home as a daily pill.
- “The treatments that we use for patients with CLL have really changed over the past decade or so,” says Dr. Kieron Dunleavy at MedStar Georgetown University Hospital at the Georgetown Lombardi Comprehensive Cancer Center.
- Two drug classes — BTK inhibitors and BCL-2 inhibitors — are driving the shift, targeting specific molecular pathways that CLL and SLL cells depend on to survive, rather than broadly attacking all dividing cells the way chemotherapy does.
- The FDA’s approval of pirtobrutinib (Jaypirca) has expanded options for patients with relapsed or refractory CLL/SLL, offering a non-covalent BTK inhibitor that can remain effective even after a patient’s disease has stopped responding to an earlier-generation drug in the same class.
Today, targeted medications like Bruton’s tyrosine kinase (BTK) inhibitors are a key part of CLL treatment, with newer drugs such as pirtobrutinib (Jaypirca) expanding options for patients whose disease has stopped responding to earlier therapies.
Read MoreFrom Chemotherapy to Targeted Therapy
Two classes of drugs have driven this shift: BTK inhibitors and BCL-2 inhibitors. Both target specific molecular pathways that CLL and SLL cells depend on to survive, rather than broadly attacking all dividing cells the way chemotherapy does, which contributes to chemo’s notorious grueling side effects.BTK inhibitors work by blocking Bruton’s tyrosine kinase, an enzyme that sits inside a signaling pathway that CLL and SLL cells rely on.
“They inhibit a key enzyme that’s involved in a critical pathway in CLL and SLL,” Dr. Dunleavy explains to SurvivorNet. Shutting down that pathway is highly effective at controlling the disease.
Two Generations of BTK Inhibitors
The first BTK inhibitor to reach the clinic was ibrutinib (Imbruvica), followed by additional drugs in the same category. These earlier drugs are known as covalent BTK inhibitors, meaning they bind permanently to the BTK enzyme. They remain widely used and highly effective in CLL and SLL.
More recently, a second type of BTK inhibitor — a non-covalent (or reversible) BTK inhibitor — has entered the treatment landscape. The first drug of this type approved for CLL/SLL is pirtobrutinib (Jaypirca). Since it binds to BTK differently than the covalent drugs, it can remain effective even after a patient’s disease has stopped responding to an earlier-generation BTK inhibitor.
“It is a highly effective BTK inhibitor,” Dr. Dunleavy says of pirtobrutinib, describing it as “a new type of Bruton’s tyrosine kinase inhibitor that has very high activity in CLL and SLL.”
How Pirtobrutinib’s Approval Has Expanded
Pirtobrutinib’s use in CLL and SLL has broadened over time as more clinical trial evidence has emerged.
- 2023: The FDA granted accelerated approval to pirtobrutinib for adults with CLL or SLL who had already received at least two prior lines of therapy, including both a covalent BTK inhibitor and a BCL-2 inhibitor.
- 2025: Based on results from the Phase 3 BRUIN-CLL-321 trial, the FDA converted that accelerated approval to full (traditional) approval and broadened the indication to adults with relapsed or refractory CLL/SLL who have previously received a covalent BTK inhibitor — meaning it no longer requires two full prior lines of treatment.
- Ongoing investigation: Pirtobrutinib is also being studied in patients who have not yet received any treatment for CLL. Dr. Dunleavy notes that early trial results in this newly diagnosed setting have been promising, though the drug is not yet FDA-approved for use as an initial therapy.
As Dr. Dunleavy adds, pirtobrutinib “was approved a few years ago by the FDA for patients with CLL and SLL who had had two previous lines of treatment. And then it was more recently approved by the FDA for patients who had had one line of treatment before.”
Expert Resources for CLL Patients
- CLL is Not Considered Curable So Treatment May Resume Years Later
- CLL Treatment: The Side Effects to Expect & Why Reporting All New Symptoms is Crucial
- CLL Treatment Decision Making — Exploring All Your Options To Find What’s Right For You
- BTK Inhibitors: Finding The Right Fit For Chronic Lymphocytic Leukemia (CLL) Patients
- BTK Inhibitors: Monitoring and Managing Side Effects During CLL Treatment
What This Means for Patients
For someone newly diagnosed with CLL, this evolving landscape means more options and more flexibility than just five years ago. If a first BTK inhibitor stops working or needs to be switched for another reason, a non-covalent option like pirtobrutinib may still be effective, extending the benefit of targeting the BTK pathway even after progression on an earlier drug in the same class.
Patients considering any BTK inhibitor should talk with their hematologist-oncologist about where a given drug fits into their personal treatment sequence, since decisions depend on prior treatments, disease characteristics, and individual health factors.
Learn more about SurvivorNet's rigorous medical review process.
